1. Home
  2. BLTE vs HSAI Comparison

BLTE vs HSAI Comparison

Compare BLTE & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLTE
  • HSAI
  • Stock Information
  • Founded
  • BLTE 2018
  • HSAI 2014
  • Country
  • BLTE United States
  • HSAI China
  • Employees
  • BLTE N/A
  • HSAI N/A
  • Industry
  • BLTE Biotechnology: Pharmaceutical Preparations
  • HSAI
  • Sector
  • BLTE Health Care
  • HSAI
  • Exchange
  • BLTE Nasdaq
  • HSAI Nasdaq
  • Market Cap
  • BLTE 1.9B
  • HSAI 1.8B
  • IPO Year
  • BLTE 2022
  • HSAI 2023
  • Fundamental
  • Price
  • BLTE $61.10
  • HSAI $16.36
  • Analyst Decision
  • BLTE Strong Buy
  • HSAI
  • Analyst Count
  • BLTE 4
  • HSAI 0
  • Target Price
  • BLTE $96.67
  • HSAI N/A
  • AVG Volume (30 Days)
  • BLTE 29.7K
  • HSAI 6.1M
  • Earning Date
  • BLTE 05-14-2025
  • HSAI 05-26-2025
  • Dividend Yield
  • BLTE N/A
  • HSAI N/A
  • EPS Growth
  • BLTE N/A
  • HSAI N/A
  • EPS
  • BLTE N/A
  • HSAI N/A
  • Revenue
  • BLTE N/A
  • HSAI $284,577,139.00
  • Revenue This Year
  • BLTE N/A
  • HSAI $68.50
  • Revenue Next Year
  • BLTE N/A
  • HSAI $35.77
  • P/E Ratio
  • BLTE N/A
  • HSAI N/A
  • Revenue Growth
  • BLTE N/A
  • HSAI 10.66
  • 52 Week Low
  • BLTE $40.00
  • HSAI $3.52
  • 52 Week High
  • BLTE $86.53
  • HSAI $24.18
  • Technical
  • Relative Strength Index (RSI)
  • BLTE 51.45
  • HSAI 51.78
  • Support Level
  • BLTE $59.04
  • HSAI $17.18
  • Resistance Level
  • BLTE $62.55
  • HSAI $19.40
  • Average True Range (ATR)
  • BLTE 2.51
  • HSAI 1.42
  • MACD
  • BLTE 0.32
  • HSAI 0.21
  • Stochastic Oscillator
  • BLTE 74.06
  • HSAI 58.64

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. The Group organized its operations into two segments: the LiDAR segment and the gas detection segment, out of which LiDAR segments derives maximum revenue. Geographically, the company operates into North America, Mainland China, Europe and Other regions.

Share on Social Networks: